ICMJE DISCLOSURE FORM

Date: 2021/8/10
Your Name: Yafei Shi
Manuscript Title: Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China
Manuscript number (if known): 

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
|   | **Time frame: Since the initial planning of the work**                                                                                         |                                                                                  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | CAMS Innovation Fund for Medical Sciences (CIFMS)(grant Nos. 2016-I2M-1-001,2017-I2M-1-005, and 2017-I2M-1-003) Payments were made to our institution |
|   | **Time frame: past 36 months**                                                               |                                                                                  |
| 2 | Grants or contracts from                                                                     | ____None                                                                         |
|   |   |
|---|---|
| 1 | any entity (if not indicated in item #1 above). |
| 3 | Royalties or licenses | None |
| 4 | Consulting fees | None |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None |
| 6 | Payment for expert testimony | None |
| 7 | Support for attending meetings and/or travel | None |
| 8 | Patents planned, issued or pending | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None |
| 11 | Stock or stock options | None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None |
| 13 | Other financial or non-financial interests | None |

**Please summarize the above conflict of interest in the following box:**

This work was supported by the CAMS Innovation Fund for Medical Sciences (CIFMS) (grant Nos. 2016-I2M-1-001, 2017-I2M-1-005, and 2017-I2M-1-003) and Bethune Foundation for Medical Science Research (B19424HN). Payments were made to our institution.
Please place an “X” next to the following statement to indicate your agreement:

X __ I certify that I have answered every question and have not altered the wording of any of the questions on this form. X
ICMJE DISCLOSURE FORM

Date: 2021/8/10
Your Name: Wei Chen
Manuscript Title: Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China
Manuscript number (if known): 

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| **Time frame: Since the initial planning of the work** |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | CAMS Innovation Fund for Medical Sciences (CIFMS)(grant Nos. 2016-I2M-1-001, 2017-I2M-1-005, and 2017-I2M-1-003) Payments were made to our institution |
|   | Bethune Foundation for Medical Science Research (B19424HN) | Payments were made to our institution |
| 2 | Grants or contracts from | None |

| **Time frame: past 36 months** |
| 2 | Grants or contracts from | None |
|   |   |   |
|---|---|---|
| Any entity (if not indicated in item #1 above). |   |   |
| Royalties or licenses | None |   |
| Consulting fees | None |   |
| Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None |   |
| Payment for expert testimony | None |   |
| Support for attending meetings and/or travel | None |   |
| Patents planned, issued or pending | None |   |
| Participation on a Data Safety Monitoring Board or Advisory Board | None |   |
| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None |   |
| Stock or stock options | None |   |
| Receipt of equipment, materials, drugs, medical writing, gifts or other services | None |   |
| Other financial or non-financial interests | None |   |

Please summarize the above conflict of interest in the following box:

This work was supported by the CAMS Innovation Fund for Medical Sciences (CIFMS) (grant Nos. 2016-I2M-1-001, 2017-I2M-1-005, and 2017-I2M-1-003) and Bethune Foundation for Medical Science Research (B19424HN). Payments were made to our institution.
Please place an “X” next to the following statement to indicate your agreement:

X  I certify that I have answered every question and have not altered the wording of any of the questions on this form.  X
ICMJE DISCLOSURE FORM

Date: 2021/8/10

Your Name: Yujun Zhang

Manuscript Title: Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| **Time frame: Since the initial planning of the work** | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | CAMS Innovation Fund for Medical Sciences (CIFMS) (grant Nos. 2016-I2M-1-001, 2017-I2M-1-005, and 2017-I2M-1-003) Payments were made to our institution |
| 2 | Grants or contracts from | Bethune Foundation for Medical Science Research (B19424HN) Payments were made to our institution |

| **Time frame: past 36 months** | |
|---|---|
| 2 | None |
|   | Description                                                                                                                                                                                                 | Response |
|---|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
|   | any entity (if not indicated in item #1 above).                                                                                                                                                              |          |
| 3 | Royalties or licenses                                                                                                                                                                                     | None     |
| 4 | Consulting fees                                                                                                                                                                                           | None     |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events                                                                                             | None     |
| 6 | Payment for expert testimony                                                                                                                                                                              | None     |
| 7 | Support for attending meetings and/or travel                                                                                                                                                               | None     |
| 8 | Patents planned, issued or pending                                                                                                                                                                          | None     |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board                                                                                                                                          | None     |
|10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid                                                                                                            | None     |
|11 | Stock or stock options                                                                                                                                                                                    | None     |
|12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services                                                                                                                           | None     |
|13 | Other financial or non-financial interests                                                                                                                                                                | None     |

Please summarize the above conflict of interest in the following box:

This work was supported by the CAMS Innovation Fund for Medical Sciences (CIFMS) (grant Nos. 2016-I2M-1-001, 2017-I2M-1-005, and 2017-I2M-1-003) and Bethune Foundation for Medical Science Research (B19424HN). Payments were made to our institution.
Please place an “X” next to the following statement to indicate your agreement:

_ X ___ I certify that I have answered every question and have not altered the wording of any of the questions on this form. X
ICMJE DISCLOSURE FORM

Date: 2021/8/10

Your Name: Mingming Bo

Manuscript Title: Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| #  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1  | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)<br>No time limit for this item. | CAMS Innovation Fund for Medical Sciences (CIFMS)(grant Nos. 2016-I2M-1-001, 2017-I2M-1-005, and 2017-I2M-1-003)<br>Payments were made to our institution |
|    | Bethune Foundation for Medical Science Research (B19424HN) | Payments were made to our institution |
|    | | |
|    | | |
|    | | |

Time frame: past 36 months

| #  | Grants or contracts from | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--------------------------|----------------------------------------------------------------------------------|
| 2  | None                     |                                                                                  |
|   |   |   |
|---|---|---|
| any entity (if not indicated in item #1 above). |   |   |
| 3  | Royalties or licenses | ___None |
| 4  | Consulting fees | ___None |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ___None |
| 6  | Payment for expert testimony | ___None |
| 7  | Support for attending meetings and/or travel | ___None |
| 8  | Patents planned, issued or pending | ___None |
| 9  | Participation on a Data Safety Monitoring Board or Advisory Board | ___None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ___None |
| 11 | Stock or stock options | ___None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ___None |
| 13 | Other financial or non-financial interests | ___None |

Please summarize the above conflict of interest in the following box:

This work was supported by the CAMS Innovation Fund for Medical Sciences (CIFMS) (grant Nos. 2016-I2M-1-001, 2017-I2M-1-005, and 2017-I2M-1-003) and Bethune Foundation for Medical Science Research (B19424HN). Payments were made to our institution.
Please place an “X” next to the following statement to indicate your agreement:

_ X ___ I certify that I have answered every question and have not altered the wording of any of the questions on this form.  X
ICMJE DISCLOSURE FORM

Date: ___2021/8/10___
Your Name: ___Chunyu Li___
Manuscript Title: ___Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China___
Manuscript number (if known): ________________________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | CAMS Innovation Fund for Medical Sciences (CIFMS)(grant Nos. 2016-I2M-1-001,2017-I2M-1-005, and 2017-I2M-1-003) Payments were made to our institution |
|   | Bethune Foundation for Medical Science Research (B19424HN) | Payments were made to our institution |
| **2** | Grants or contracts from | ____None |

**Time frame: Since the initial planning of the work**

**Time frame: past 36 months**
|   | Description                                                                                                                                   | Response |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------|----------|
| 1 | any entity (if not indicated in item #1 above).                                                                                               |          |
| 3 | Royalties or licenses                                                                                                                          | None     |
| 4 | Consulting fees                                                                                                                                | None     |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None     |
| 6 | Payment for expert testimony                                                                                                                  | None     |
| 7 | Support for attending meetings and/or travel                                                                                                  | None     |
| 8 | Patents planned, issued or pending                                                                                                             | None     |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board                                                                             | None     |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid                                            | None     |
| 11| Stock or stock options                                                                                                                         | None     |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services                                                             | None     |
| 13| Other financial or non-financial interests                                                                                                     | None     |

**Please summarize the above conflict of interest in the following box:**

This work was supported by the CAMS Innovation Fund for Medical Sciences (CIFMS) (grant Nos. 2016-I2M-1-001, 2017-I2M-1-005, and 2017-I2M-1-003) and Bethune Foundation for Medical Science Research (B19424HN). Payments were made to our institution.
Please place an “X” next to the following statement to indicate your agreement:

_ X ___ I certify that I have answered every question and have not altered the wording of any of the questions on this form. X
ICMJE DISCLOSURE FORM

Date: ____2021/8/10____
Your Name: Mingyu Zhang
Manuscript Title: Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China
Manuscript number (if known): 

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| **Time frame: Since the initial planning of the work** | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | CAMS Innovation Fund for Medical Sciences (CIFMS)(grant Nos. 2016-I2M-1-001,2017-I2M-1-005, and 2017-I2M-1-003) Payments were made to our institution |
|   | Bethune Foundation for Medical Science Research (B19424HN) | Payments were made to our institution |

| **Time frame: past 36 months** | | |
| 2 | Grants or contracts from | None |
|   |   |   |
|---|---|---|
| any entity (if not indicated in item #1 above). |   |   |
| 3 | Royalties or licenses | ___ None |
| 4 | Consulting fees | ___ None |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ___ None |
| 6 | Payment for expert testimony | ___ None |
| 7 | Support for attending meetings and/or travel | ___ None |
| 8 | Patents planned, issued or pending | ___ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | ___ None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ___ None |
| 11 | Stock or stock options | ___ None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ___ None |
| 13 | Other financial or non-financial interests | ___ None |

Please summarize the above conflict of interest in the following box:

This work was supported by the CAMS Innovation Fund for Medical Sciences (CIFMS) (grant Nos. 2016-I2M-1-001, 2017-I2M-1-005, and 2017-I2M-1-003) and Bethune Foundation for Medical Science Research (B19424HN). Payments were made to our institution.
Please place an “X” next to the following statement to indicate your agreement:

_ X __ I certify that I have answered every question and have not altered the wording of any of the questions on this form.  X
ICMJE DISCLOSURE FORM

Date: 2021/8/10
Your Name: Guohui Li
Manuscript Title: Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China
Manuscript number (if known): 

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
|1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | CAMS Innovation Fund for Medical Sciences (CIFMS)(grant Nos. 2016-I2M-1-001, 2017-I2M-1-005, and 2017-I2M-1-003) |
|   | **No time limit for this item.** | Payments were made to our institution |
|   | Bethune Foundation for Medical Science Research (B19424HN) | Payments were made to our institution |

|   | Time frame: past 36 months |
|---|-----------------------------|
|2 | Grants or contracts from | **None** |
| Item | Description | Note |
|------|-------------|------|
| 1.  | any entity (if not indicated in item #1 above) | |
| 3.  | Royalties or licenses | None |
| 4.  | Consulting fees | None |
| 5.  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None |
| 6.  | Payment for expert testimony | None |
| 7.  | Support for attending meetings and/or travel | None |
| 8.  | Patents planned, issued or pending | None |
| 9.  | Participation on a Data Safety Monitoring Board or Advisory Board | None |
| 10. | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None |
| 11. | Stock or stock options | None |
| 12. | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None |
| 13. | Other financial or non-financial interests | None |

Please summarize the above conflict of interest in the following box:

This work was supported by the CAMS Innovation Fund for Medical Sciences (CIFMS) (grant Nos. 2016-I2M-1-001, 2017-I2M-1-005, and 2017-I2M-1-003) and Bethune Foundation for Medical Science Research (B19424HN). Payments were made to our institution.
Please place an “X” next to the following statement to indicate your agreement:

_ X ___ I certify that I have answered every question and have not altered the wording of any of the questions on this form.  X